It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

The author has completed the ICMJE form and declares the following conflicts of interest: She is a research assistant and principal investigator at a fetal medicine centre involved in the nipocalimab ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Additionally, the company will need to navigate the competitive landscape in areas like generalized myasthenia gravis (gMG), where nipocalimab will face entrenched players. Looking ahead, Johnson & ...

Additionally, the company will need to navigate the competitive landscape in areas like generalized myasthenia gravis (gMG), where nipocalimab will face entrenched players. Looking ahead ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The Lancet Neurology. J&J is testing the investigational FcRn blocker in a broad ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...